Geode Capital Management’s Curanex Pharmaceuticals CURX Stock Holding History

Geode Capital Management’s Portfolio CURX Stock Details CURX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.8K	Buy	111,130 +92,460	+495%	+$34.7K	﹤0.01%	4284
2025 Q4	$6.17K	Hold	18,670	–	–	﹤0.01%	4451
2025 Q3	$13.4K	Buy	+18,670	New	+$84.5K	﹤0.01%	4439

Other funds holding CURX

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management's CURX Position: Q1 2026 in Review

Geode Capital Management increased its Curanex Pharmaceuticals (CURX) stake by 495% in Q1 2026, buying an estimated $34.7K and bringing the position to 111,130 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4284.

Geode Capital Management first reported a position in CURX in Q3 2025 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold CURX as of Q1 2026.

Geode Capital Management held 111,130 shares of Curanex Pharmaceuticals worth $56.8K as of Q1 2026.
Geode Capital Management bought 92,460 Curanex Pharmaceuticals shares in Q1 2026, an estimated $34.7K.
Curanex Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4284 holding.
Geode Capital Management first reported a position in Curanex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
8 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.